Navigation Links
Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device
Date:4/7/2008

Innovative Device Recognized for Design Excellence and Patient Ease-of-Use

BROOKFIELD, Wis., April 7, 2008 /PRNewswire-FirstCall/ -- Honeywell (NYSE: HON) today won the 2008 Medical Design Excellence Awards (MDEA) for its Genesis(TM) DM remote patient care device. The Genesis DM won in the rehabilitation and assistive-technology products category.

The award-winning Honeywell HomMed remote patient monitoring device is ideal for both the patient and the medical professional, using text or voice prompts to guide patients through a series of yes/no questions that allow medical professionals to monitor and receive a thorough health assessment.

The Honeywell HomMed remote patient monitoring device is part of the LifeStream Ecosystem and provides patients with an easy-to-use device for the home. The three-part LifeStream ecosystem, providing cost-effective care for patients at home, includes the patient-facing Genesis DM device, software applications and service. Patients suffering from a variety of chronic conditions, such as congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, diabetes and hypertension, can use the Genesis DM device to assess their condition in the privacy of their homes. This information is transmitted securely over the internet to their caregiver for monitoring and the appropriate intervention if necessary.

"When designing the Genesis DM, we listened to the ultimate customer -- patients. Without more consistent patient use of telemonitoring, the delivery of telehealth cannot be optimized," said Mike Benjamin, president of Honeywell HomMed. "We're honored to receive this recognition and proud of the team at Honeywell HomMed who made this possible. Our focus continues to be ensuring chronically ill patient's independent living with dignity for at an affordable cost."

"It is very important to us to provide our patients and caregivers with the most meaningful information with regards to patient health," said Terry Duesterhoeft, vice president of Marketing & Sales, Honeywell. "As we developed the Genesis DM, we closely evaluated the entire patient environment and discovered that the integration of all data (both objective and subjective) truly differentiated this product in the overall telehealth ecosystem."

The Medical Design Excellence Awards, now in its eleventh year, recognizes companies and individuals worldwide involved in the design, engineering, manufacture or distribution of finished medical devices or medical packaging. Entries are evaluated by a multidisciplinary panel of jurors with expertise in engineering, medicine, industrial design, manufacturing and other design -- and healthcare-related fields.

For more information about Honeywell HomMed's telehealth solutions, visit http://www.hommed.com.

About Honeywell

Honeywell International is a $36 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London and Chicago Stock Exchanges. For additional information, please visit http://www.honeywell.com.

Forward Looking Statement

This release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Honeywell
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
2. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
3. Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus
4. ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million
5. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
6. Tryton Medical, Inc. Closes $14 Million Financing
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
9. Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call
10. Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Insights, 2016", report provides in depth insights ... activities around the Protein-Tyrosine Phosphatase 1B (PTP1B) ... profiles in various stages of development including ... Phase III and Preregistration. Report covers the ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016 Novan, Inc. today ... Chairman of the Board of Directors of Novan. In addition, ... North Carolina . --> ... Company also announced that it received a total of $32.8 million ... 2015 from its private investor network originating throughout the Research Triangle ...
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. , an ... technology, today announced the availability of AllegroGraph 6, the leading Semantic Graph Database ... Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph Database to ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):